{"id":"https://openalex.org/W4416639286","doi":"https://doi.org/10.1183/13993003.congress-2025.pa5697","title":"Real-world outcomes of Budesonide/Glycopyrronium/Formoterol therapy in COPD after 12 months; the RECORD study","display_name":"Real-world outcomes of Budesonide/Glycopyrronium/Formoterol therapy in COPD after 12 months; the RECORD study","publication_year":2025,"publication_date":"2025-09-27","ids":{"openalex":"https://openalex.org/W4416639286","doi":"https://doi.org/10.1183/13993003.congress-2025.pa5697"},"language":"en","primary_location":{"id":"doi:10.1183/13993003.congress-2025.pa5697","doi":"https://doi.org/10.1183/13993003.congress-2025.pa5697","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2025.pa5697","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Airway pharmacology and treatment","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5087999170","display_name":"Henrik Watz","orcid":"https://orcid.org/0000-0003-1506-2661","observed_orcids":["https://orcid.org/0000-0003-1506-2661"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Henrik Watz","raw_affiliation_strings":["1Velocity Clinical Research Germany, Ahrensburg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Velocity Clinical Research Germany, Ahrensburg, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111100217","display_name":"Marija Halbach","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marija Halbach","raw_affiliation_strings":["2Medical Evidence, BioPharmaceuticals, AstraZeneca GmbH, Hamburg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Medical Evidence, BioPharmaceuticals, AstraZeneca GmbH, Hamburg, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053091310","display_name":"Matthias Saathoff","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthias Saathoff","raw_affiliation_strings":["2Medical Evidence, BioPharmaceuticals, AstraZeneca GmbH, Hamburg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Medical Evidence, BioPharmaceuticals, AstraZeneca GmbH, Hamburg, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031998337","display_name":"Tamsin Morris","orcid":"https://orcid.org/0000-0003-4475-5483","observed_orcids":["https://orcid.org/0000-0003-4475-5483"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Tamsin Morris","raw_affiliation_strings":["3Medical and Scientific affairs, BioPharmaceuticals, AstraZeneca UK, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Medical and Scientific affairs, BioPharmaceuticals, AstraZeneca UK, London, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057618841","display_name":"Michael Watt","orcid":"https://orcid.org/0009-0005-4313-5735","observed_orcids":["https://orcid.org/0009-0005-4313-5735"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Michael Watt","raw_affiliation_strings":["3Medical and Scientific affairs, BioPharmaceuticals, AstraZeneca UK, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Medical and Scientific affairs, BioPharmaceuticals, AstraZeneca UK, London, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Annika Fernandez Milano","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Annika Fernandez Milano","raw_affiliation_strings":["4IQVIA Commercial GmbH & Co. OHG, Frankfurt am Main, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4IQVIA Commercial GmbH & Co. OHG, Frankfurt am Main, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046587595","display_name":"Dinesh Shrikrishna","orcid":"https://orcid.org/0009-0004-3663-4512","observed_orcids":["https://orcid.org/0009-0004-3663-4512"]},"institutions":[{"id":"https://openalex.org/I2800820451","display_name":"Musgrove Park Hospital","ror":"https://ror.org/042fv2404","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800820451"]},{"id":"https://openalex.org/I4210122580","display_name":"Taunton & Somerset NHS Foundation Trust","ror":"https://ror.org/02y5f7327","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I4210122580","https://openalex.org/I4401726752"]},{"id":"https://openalex.org/I4401726752","display_name":"Somerset NHS Foundation Trust","ror":"https://ror.org/00abj3t43","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4401726752"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Dinesh Shrikrishna","raw_affiliation_strings":["5Department of Respiratory Medicine, Musgrove Park Hospital, Somerset NHS Foundation Trust, Taunton, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Department of Respiratory Medicine, Musgrove Park Hospital, Somerset NHS Foundation Trust, Taunton, United Kingdom","institution_ids":["https://openalex.org/I2800820451","https://openalex.org/I4210122580","https://openalex.org/I4401726752"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5068917661","display_name":"Dave Singh","orcid":"https://orcid.org/0000-0001-8918-7075","observed_orcids":["https://orcid.org/0000-0001-8918-7075"]},"institutions":[{"id":"https://openalex.org/I28407311","display_name":"University of Manchester","ror":"https://ror.org/027m9bs27","country_code":"GB","type":"education","lineage":["https://openalex.org/I28407311"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Dave Singh","raw_affiliation_strings":["6University of Manchester, Manchester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6University of Manchester, Manchester, United Kingdom","institution_ids":["https://openalex.org/I28407311"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"PA5697","last_page":"PA5697"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10143","display_name":"Chronic Obstructive Pulmonary Disease (COPD) Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10143","display_name":"Chronic Obstructive Pulmonary Disease (COPD) Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11651","display_name":"Inhalation and Respiratory Drug Delivery","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-obstructive-pulmonary-disease","display_name":"chronic obstructive pulmonary disease","score":0.7609999775886536},{"id":"https://openalex.org/keywords/budesonide-glycopyrronium-formoterol","display_name":"budesonide/glycopyrronium/formoterol","score":0.9660000205039978},{"id":"https://openalex.org/keywords/triple-therapy","display_name":"triple therapy","score":0.6010000109672546},{"id":"https://openalex.org/keywords/acute-exacerbation-of-copd","display_name":"COPD exacerbations","score":0.9010000228881836},{"id":"https://openalex.org/keywords/lung-function","display_name":"lung function","score":0.7910000085830688},{"id":"https://openalex.org/keywords/fev1","display_name":"FEV1","score":0.781000018119812},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.746999979019165},{"id":"https://openalex.org/keywords/copd-assessment-test","display_name":"COPD Assessment Test","score":0.9520000219345093},{"id":"https://openalex.org/keywords/st-george-s-respiratory-questionnaire","display_name":"St George's Respiratory Questionnaire","score":0.9879999756813049},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.9369999766349792},{"id":"https://openalex.org/keywords/treatment-satisfaction","display_name":"treatment satisfaction","score":0.9169999957084656},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.8769999742507935},{"id":"https://openalex.org/keywords/real-world-effectiveness","display_name":"real-world effectiveness","score":0.7789999842643738}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9484999775886536},{"id":"https://openalex.org/C2777014857","wikidata":"https://www.wikidata.org/wiki/Q1383410","display_name":"Exacerbation","level":2,"score":0.7520999908447266},{"id":"https://openalex.org/C2776780178","wikidata":"https://www.wikidata.org/wiki/Q199804","display_name":"COPD","level":2,"score":0.7396000027656555},{"id":"https://openalex.org/C111278954","wikidata":"https://www.wikidata.org/wiki/Q17069312","display_name":"Minimal clinically important difference","level":3,"score":0.6162999868392944},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.5562000274658203},{"id":"https://openalex.org/C2779159551","wikidata":"https://www.wikidata.org/wiki/Q1414874","display_name":"Comorbidity","level":2,"score":0.5410000085830688},{"id":"https://openalex.org/C23131810","wikidata":"https://www.wikidata.org/wiki/Q818574","display_name":"Observational study","level":2,"score":0.5260000228881836},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.48840001225471497},{"id":"https://openalex.org/C195910791","wikidata":"https://www.wikidata.org/wiki/Q1324077","display_name":"Medical record","level":2,"score":0.4781000018119812},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4350000023841858},{"id":"https://openalex.org/C2910217193","wikidata":"https://www.wikidata.org/wiki/Q4677923","display_name":"Copd exacerbation","level":4,"score":0.39660000801086426},{"id":"https://openalex.org/C194828623","wikidata":"https://www.wikidata.org/wiki/Q2861470","display_name":"Emergency medicine","level":1,"score":0.323199987411499},{"id":"https://openalex.org/C2984752397","wikidata":"https://www.wikidata.org/wiki/Q3259956","display_name":"Primary care","level":2,"score":0.32100000977516174},{"id":"https://openalex.org/C2780779891","wikidata":"https://www.wikidata.org/wiki/Q3455927","display_name":"Pulmonary rehabilitation","level":3,"score":0.3165999948978424},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.2750000059604645},{"id":"https://openalex.org/C2775944032","wikidata":"https://www.wikidata.org/wiki/Q22907659","display_name":"Patient satisfaction","level":2,"score":0.27239999175071716},{"id":"https://openalex.org/C2776178081","wikidata":"https://www.wikidata.org/wiki/Q3286546","display_name":"Respiratory disease","level":3,"score":0.2639999985694885},{"id":"https://openalex.org/C534529494","wikidata":"https://www.wikidata.org/wiki/Q7891","display_name":"Respiratory system","level":2,"score":0.2542000114917755}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1183/13993003.congress-2025.pa5697","doi":"https://doi.org/10.1183/13993003.congress-2025.pa5697","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2025.pa5697","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Airway pharmacology and treatment","raw_type":"proceedings-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4404098550","https://openalex.org/W4408555366","https://openalex.org/W4404096775","https://openalex.org/W7171666577","https://openalex.org/W4414394984","https://openalex.org/W4411194318","https://openalex.org/W4416636478","https://openalex.org/W4416634746","https://openalex.org/W7163176070","https://openalex.org/W7019291993"],"abstract_inverted_index":{"RECORD":[0],"is":[1,200],"an":[2,170],"observational":[3],"single":[4],"arm":[5],"study":[6],"investigating":[7],"effectiveness":[8],"of":[9,33,175,212],"Budesonide/Glycopyrronium/Formoterol":[10],"(BGF)":[11],"therapy":[12],"in":[13,111,162,172,189,205],"patients":[14],"(pts)":[15],"with":[16,27,202],"COPD":[17,28],"from":[18,42],"Germany":[19],"and":[20,45,61,78,127,142,147,158,210],"United":[21],"Kingdom":[22],"over":[23,68,197],"12":[24,69,114,148,198],"months.":[25,115],"Pts":[26],"were":[29,66,73,86],"enrolled":[30],"following":[31],"initiation":[32],"BGF":[34,195],"according":[35],"to":[36],"label.":[37],"Outcomes":[38],"\u2014":[39,65],"including":[40],"exacerbations":[41],"medical":[43],"records":[44],"patient":[46],"reported":[47],"outcomes":[48,155],"(COPD":[49],"Assessment":[50],"Test":[51],"(CAT),":[52],"St.":[53],"George's":[54],"Respiratory":[55],"Questionnaire":[56],"(SGRQ),":[57],"treatment":[58,196],"satisfaction":[59],"(TSQM-9)":[60],"medication":[62],"adherence":[63],"(MARS\u20105))":[64],"measured":[67],"months":[70,199],"post-initiation.":[71],"There":[72],"571":[74],"pts":[75,80],"at":[76,81,124,130,145,156],"baseline":[77],"426":[79],"M12.":[82],"At":[83,165],"BL":[84,125,146,157],"44.1%":[85],"female,":[87],"mean":[88],"(SD)":[89,117],"age":[90],"was":[91,101,121,139],"65.5":[92],"(10.7)":[93],"years,":[94],"45.7%":[95],"current":[96],"smokers,":[97],"most":[98],"common":[99],"comorbidity":[100],"hypertension":[102],"(46.2%);":[103],"35.6%":[104],"had":[105,169,185],"experienced":[106],"moderate":[107],"or":[108],"severe":[109],"exacerbation(s)":[110],"the":[112,163],"prior":[113],"Mean":[116,133],"%":[118],"predicted":[119],"FEV1":[120],"56.2%":[122],"(18.2%)":[123],"(n=320)":[126],"63.0%":[128],"(19.8%)":[129],"M12":[131,166],"(n=185).":[132],"annual":[134],"exacerbation":[135,206],"rate":[136],"(95%":[137],"CI)":[138],"0.74":[140],"(0.68,0.82)":[141],"0.45":[143],"(0.39,0.52)":[144],"months,":[149],"respectively":[150],"(40%":[151],"relative":[152],"reduction).":[153],"PRO":[154],"M3":[159],"are":[160],"presented":[161],"table.":[164],"49.3%":[167],"(n=217)":[168],"improvement":[171],"CAT":[173],"score":[174],"\u22652":[176],"points":[177],"(minimal":[178],"clinically":[179],"important":[180],"difference":[181],"[MCID]);":[182],"53.1%":[183],"(N=209)":[184],"MCID":[186],"(\u22654)":[187],"change":[188],"SGRQ.":[190],"These":[191],"results":[192],"suggest":[193],"that":[194],"associated":[201],"sustained":[203],"improvements":[204],"rates,":[207],"lung":[208],"function,":[209],"quality":[211],"life.":[213],"erj;66/suppl_69/PA5697/F1":[214],"F1":[215,216]},"counts_by_year":[],"updated_date":"2026-11-01T11:40:01.658920","created_date":"2025-11-25T00:00:00"}